Neuraxpharm Group enters the CBD market with the acquisition of S.T.U. GmbH
31 October 2019 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the central nervous system (CNS), acquires S.T.U. GmbH, a leading Switzerland-based developer and distributor of natural cannabidiol (CBD) consumer products. The deal enables Neuraxpharm to enter the fast-growing CBD space and to build on its business of CNS-related products, including value added medicines, standard generics and consumer healthcare products.
Walder Wyss advised Neuraxpharm on the transaction. The team was led by Stefan Knobloch (Corporate/M&A, Partner) and Fabienne Anner (Corporate/M&A, Managing Associate) and further included Michael Isler (Regulatory/IP/IT, Partner), Annemarie Lagger (Regulatory/IP/IT, Associate), Benno Fischer-Siddiqui (IP/IT, Associate), Monja Sieber (IP/IT, Associate), Thomas Meister (Tax, Partner) and Nathalie Möri (Employment, Associate).